II型糖尿病市場的PROactive研究

本報告已在2011年12月21日停止出版。

簡介

目錄

Abstract

The life-threatening complications of type 2 diabetes constitute a significant unmet medical need worldwide, particularly because the prevalence of type 2 diabetes has soared in recent years as a result of changing eating habits and lifestyles. The current selection of antidiabetic drugs successfully manage the disease, but until the late 2005 release of results from the Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive) study, no data quantified the effects of antidiabetic drugs on the incidence of cardiovascular disease (CVD). While the results of the PROactive study suggest that pioglitazone, a peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist, may mitigate the occurrence of cardiovascular events in type 2 diabetes patients with a history of CVD, certain aspects of the PROactive study have been a cause for concern among members of the medical community. This report discusses the PROactive study, beginning with an overview of type 2 diabetes, including information on its increasing prevalence and associated comorbidities, particularly cardiovascular complications, and available therapies. Next, we discuss pioglitazone's pharmacological profile as well as the design, results, and possible shortcomings of this breakthrough trial. Finally, we forecast the potential effect of the PROactive study on sales of pioglitazone and the commercial opportunities for other antidiabetic agents.

Table of Contents

Introduction: Promising Results in the Recent PROactive Study

Type 2 Diabetes: Disease Background and Prevalence

• Pathophysiology and Risk Factors
• Type 2 Diabetes and Cardiovascular Disease
• Prevalence of Type 2 Diabetes

Overview of Current Drug Therapies

• Sulfonylureas
• Meglitinides
• Alpha-Glucosidase Inhibitors
• Biguanides
• Peroxisome Proliferator-Activated Receptor-Gamma Agonists
• Glucagon-Like Peptide-1 Analogues
• Amylin Analogues

The PROactive Study: Revealing a Potential Breakthrough Treatment for Cardiovascular Disease in

Type 2 Diabetes

• The Role of PPAR in Cardiovascular Disease
• PROactive Study Design
• PROactive Study Results
• Shortcomings of the PROactive Study

Outlook

相關商品

糖尿病相關市場調查報告書

胰島素給藥設備:全球開發平台分析機會評估及與到2017年為止的市場預測
Insulin Delivery Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
價格 : US $ 3995
出版日期 : 2012年01月

南非的糖尿病管理設備市場的機會及到2016年為止的成長趨勢預測
South Africa Diabetes Management Devices Market Outlook and Opportunities
價格 : US $ 2500
出版日期 : 2011年12月

荷蘭的糖尿病管理設備市場的機會及到2016年為止的成長趨勢預測
Netherlands Diabetes Management Devices Market Outlook and Opportunities
價格 : US $ 2500
出版日期 : 2011年12月

Decision Resources, Inc.發行的製藥相關市場調查報告書

傳染病疫苗開發平台:競爭檢討

Special Report: The Infectious Disease Vaccine Pipeline--A Competitive Review

價格 : US $ 9200

出版日期 : 2011年06月

感染疾病疫苗:未滿足需求和對醫藥品產業來說的機會

Special Report: Infectious Disease Vaccines--Unmet Needs and Opportunities for Pharma

價格 : US $ 9200

出版日期 : 2011年06月

自閉症譜系障礙:高未滿足需求創造出很大的市場機會

Special Report: Autism Spectrum Disorders--High Unmet Needs Create Significant Market Opportunities

價格 : US $ 9200

出版日期 : 2011年06月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!